I'm LongbridgeAI, I can summarize articles.Iovance Biotherapeutics updated its corporate presentation and reiterated FY2026 revenue guidance of $350M–$370M, with Q2 guidance at $86M–$88M. The company reported a cash position of ~$319M as of March 31, 2026, providing runway into 2028. Key highlights include a commercial footprint of over 90 treatment centers and ~1,500 patients treated with TIL products, alongside pipeline updates for melanoma and NSCLC programs.
Iovance Biotherapeutics updated its corporate presentation and reiterated FY2026 revenue guidance of $350M–$370M and Q2 guidance of $86M–$88M.
Key Highlights:
- Company updated corporate presentation used for healthcare conferences, analysts and stockholders; Exhibit 99.1 attached to 8-K.
- Reiterated FY2026 revenue guidance of $350M–$370M and Q2 2026 guidance of $86M–$88M.
- Reported cash position of ~$319M as of March 31, 2026, with runway into 2028.
- Highlighted commercial footprint: >90 Authorized Treatment Centers and ~1,500+ patients treated with TIL products.
- Outlined pipeline and commercial plans including frontline melanoma registrational TILVANCE-301 and fast-track NSCLC lifileucel programs.
Original SEC Filing: IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] - 8-K - Jul. 02, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.